Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVEc vaccine safety and immunogenicity
NCT02386150Phase 1Withdrawn
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Oct 2017
- Primary completion
- Dec 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of ricin vaccine RVEc in Ricin poisoning (2 arms), sponsored by U.S. Army Medical Research and Development Command. Primary endpoints: Percentage of vaccinated subjects without adverse events at Day 730, Percentage of vaccinated subjects with adverse events at Day 730 and 2 more. Planned start Oct 2017; status: withdrawn.
02
Drugs
ricin vaccine RVEc
03
Conditions
Ricin poisoning
Beyond the preview
Go deeper on NCT02386150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02386150.